| 000 | 01538 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250517131043.0 | ||
| 264 | 0 | _c20170824 | |
| 008 | 201708s 0 0 eng d | ||
| 022 | _a0392-856X | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSvensson, John | |
| 245 | 0 | 0 |
_aUse of biologic agents in idiopathic inflammatory myopathies in Sweden: a descriptive study of real life treatment. _h[electronic resource] |
| 260 |
_bClinical and experimental rheumatology _c |
||
| 300 |
_a512-515 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xadverse effects |
| 650 | 0 | 4 |
_aBiological Products _xadverse effects |
| 650 | 0 | 4 | _aDrug Substitution |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterleukin 1 Receptor Antagonist Protein _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyositis _xdiagnosis |
| 650 | 0 | 4 | _aOff-Label Use |
| 650 | 0 | 4 | _aRegistries |
| 650 | 0 | 4 |
_aRituximab _xtherapeutic use |
| 650 | 0 | 4 |
_aSweden _xepidemiology |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aHolmqvist, Marie | |
| 700 | 1 | _aTjärnlund, Anna | |
| 700 | 1 | _aDastmalchi, Maryam | |
| 700 | 1 | _aHanna, Balsam | |
| 700 | 1 | _aMagnusson Bucher, Sara | |
| 700 | 1 | _aLundberg, Ingrid E | |
| 773 | 0 |
_tClinical and experimental rheumatology _gvol. 35 _gno. 3 _gp. 512-515 |
|
| 999 |
_c26697358 _d26697358 |
||